SS Innovations (SSII) Q3 2024 Earnings Report

SS Innovations International Inc (SSII) reported QQ3 2024 revenue of $3.41 million, a year-over-year surge of 138% from $1.43 million in QQ3 2023, but bottom-line profitability remained deeply negative with an end-to-end loss trajectory that persisted from the prior period. Gross profit was $1.30 million, yielding a gross margin of 38.2%. The company incurred significant operating expenses, with R&D at $1.24 million and G&A at $5.07 million, contributing to an operating loss of $3.20 million and an EBITDA of negative $4.76 million. Net income deteriorated to negative $6.12 million, translating to a basic EPS of −$0.0358 and a diluted EPS of −$0.02. The quarter’s cash flow performance remained weak, with negative operating cash flow of approximately $2.55 million and negative free cash flow of about $0.84 million, driven by working capital dynamics (notably sizable increases in inventory and receivables) and continued capital expenditure of $1.70 million. Balance sheet metrics point to a leveraged microcap profile: total debt at $15.48 million, net debt around $15.26 million, a current ratio of 1.41, and a very low cash ratio of 0.012, underscoring liquidity risk if operating losses persist. Management commentary is not captured in the provided transcript dataset, limiting the ability to quantify strategic pivot points from the QQ3 call. Looking forward, the absence of formal forward guidance in the dataset means investors should monitor topline trajectory, unit economics, and cash burn as the company continues investing in its robotic surgery platforms (Mantra, Mudra, Maya) and the OMNI 3D HD visualization suite. The imminent inflection point will be whether incremental revenue growth translates into margin expansion and cash flow improvement at scale.